ATP5A1 — ATP Synthase Subunit Alpha
Introduction
Atp5A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@brown2014]
<table>
<tr><th colspan="2" style="background:#1a5f7a;color:white;">ATP5A1 — ATP Synthase Subunit Alpha</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ATP5A1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP Synthase Subunit Alpha</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>21q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[498](https://www.ncbi.nlm.nih.gov/gene/498)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000188039</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P25788](https://www.uniprot.org/uniprot/P25788)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Mitochondrial Dysfunction](/diseases/mitochondrial-dysfunction)</td></tr>
</table>
</div>
Overview
...ATP5A1 — ATP Synthase Subunit Alpha
Introduction
Atp5A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@brown2014]
<table>
<tr><th colspan="2" style="background:#1a5f7a;color:white;">ATP5A1 — ATP Synthase Subunit Alpha</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ATP5A1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP Synthase Subunit Alpha</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>21q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[498](https://www.ncbi.nlm.nih.gov/gene/498)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000188039</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P25788](https://www.uniprot.org/uniprot/P25788)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Mitochondrial Dysfunction](/diseases/mitochondrial-dysfunction)</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
ATP5A1 encodes the alpha subunit of mitochondrial ATP synthase (Complex V), the enzyme responsible for synthesizing ATP from ADP using the proton gradient across the inner mitochondrial membrane. This is the final step of oxidative phosphorylation.
ATP5A1 is one of the most abundant mitochondrial proteins and is essential for:
- ATP production via oxidative phosphorylation
- Mitochondrial function maintenance
- Cellular energy homeostasis
Molecular Mechanism
The mitochondrial ATP synthase (Complex V) is a large multiprotein complex consisting of over 20 subunits. ATP5A1 (encoded by nuclear DNA but imported into mitochondria) forms the central catalytic alpha subunit of the F1 domain. [@moree2023]
The enzymatic mechanism involves:
Proton Gradient Utilization: The F0 portion of the complex spans the inner mitochondrial membrane and acts as a proton channel. Protons flowing back through F0 drive the rotation of the central shaft.
Rotary Catalysis: The gamma subunit rotates within the alpha3beta3 hexamer of the F1 domain, causing conformational changes that drive ATP synthesis from ADP and inorganic phosphate (Pi).
Coupling Efficiency: ATP5A1's function is directly coupled to the electron transport chain (ETC). Any disruption in ETC complex I-IV activity reduces the proton gradient, compromising ATP synthesis capacity.Structural Details
- Protein Size: 553 amino acids, ~60 kDa
- Topology: Matrix-facing F1 domain
- Oligomeric State: Forms part of the alpha3beta3 hexamer with 3 alpha (ATP5A1) and 3 beta (ATP5B) subunits
- Post-translational Modifications: Known to be phosphorylated and acetylated, affecting enzyme activity and assembly
Function
ATP Synthesis
- Catalyzes ATP synthesis from ADP and Pi
- Uses proton motive force generated by ETC
- F1 portion contains alpha3beta3hexamer - catalytic core
Structure
- ~553 amino acids
- Molecular weight ~60 kDa
- Located in mitochondrial matrix
- Part of the F1 catalytic domain
Regulation
- Oligomycin sensitivity conferral protein (OSCP) interaction
- Inhibitory proteins (IF1) regulation
- ADP/ATP exchange via adenine nucleotide translocase
- Transcriptional regulation by PGC-1alpha (mitochondrial biogenesis master regulator)
Disease Associations
Alzheimer's Disease
Alzheimer's disease (AD) is characterized by progressive cognitive decline accompanied by neuronal loss and synaptic dysfunction. Mitochondrial dysfunction is now recognized as an early event in AD pathogenesis, with ATP5A1 playing a central role. [@brown2014]
Evidence from Human Studies:
- Reduced ATP5A1 protein expression in AD prefrontal cortex [@wang2022]
- Decreased ATP synthase activity in AD temporal gyrus
- Correlation between reduced Complex V activity and MMSE scores
- Altered ATP5A1 phosphorylation patterns in AD brain
Mechanistic Links:
- Amyloid-beta (Aβ) oligomers directly inhibit mitochondrial ATP synthase activity
- Tau pathology disrupts mitochondrial dynamics, affecting ATP synthase assembly
- Oxidative stress in AD damages ATP5A1 through carbonylation
- [Microglia](/cell-types/microglia)mediated neuroinflammation reduces neuronal ATP5A1 expression
Therapeutic Implications:
- Agents that enhance ATP synthase efficiency
- PGC-1alpha agonists to boost mitochondrial biogenesis
- Antioxidants to protect ATP5A1 from oxidative damage
Parkinson's Disease
Parkinson's disease (PD) features selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. These neurons have particularly high energy demands, making them vulnerable to mitochondrial dysfunction. [@cheng2021]
Mitochondrial Complex I Deficiency:
- The most consistent biochemical finding in PD substantia nigra
- Reduced Complex I activity leads to decreased proton pumping
- Compromised proton gradient limits ATP synthase capacity
- ATP5A1 expression is downregulated in PD brains
Mechanistic Links:
- LRRK2 mutations (common in familial PD) affect mitochondrial function
- Alpha-synuclein aggregation disrupts mitochondrial membranes
- PINK1/Parkin mitophagy pathway dysfunction
- Environmental toxins (MPTP, rotenone) inhibit Complex I
Therapeutic Implications:
- CoQ10 supplementation to support electron flow
- ATP5A1 expression modulators
- Mitochondrial turnover enhancers
Mitochondrial Disorders
Mutations in ATP5A1 cause rare but severe mitochondrial disorders: [@moree2023]
- ATP Synthase Deficiency: Reduced enzyme activity
- Mitochondrial Encephalomyopathy: Combined neurological and muscular symptoms
- Lactic Acidosis: Due to impaired oxidative phosphorylation
- Developmental Delay: In pediatric cases
- Hypertrophic Cardiomyopathy: Due to high cardiac energy demands
Amyotrophic Lateral Sclerosis (ALS)
Emerging evidence suggests ATP5A1 dysfunction may contribute to ALS pathogenesis:
- Motor neurons have exceptionally high energy requirements
- Mitochondrial dysfunction is observed in ALS spinal cord
- ATP5A1 aggregates have been reported in ALS models
Therapeutic Targets
Drug Development Approaches
| Target | Approach | Status |
|--------|----------|--------|
| ATP synthase activators | Small molecule enhancers | Preclinical |
| PGC-1alpha agonists | Increase mitochondrial biogenesis | Clinical trials |
| Antioxidants | Protect against ROS damage | Clinical trials |
| Mitochondrial stabilizers | Prevent fission/fusion defects | Preclinical |
Nutritional Interventions
- Coenzyme Q10: Supports electron transport chain
- L-carnitine: Enhances mitochondrial fatty acid transport
- Alpha-lipoic acid: Antioxidant and mitochondrial support
- Creatine: Helps maintain cellular ATP pools
Expression Pattern
ATP5A1 is ubiquitously expressed with tissue-specific levels: [@wang2022]
- Brain: High in pyramidal neurons of [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
- Heart: Very high (continuous energy demand for contractile function)
- Skeletal Muscle: High in fast-twitch fibers
- Liver: High metabolic activity
- Kidney: Energy-intensive transport processes
Cellular Localization
- Primary: Mitochondrial inner membrane (F1 domain facing matrix)
- Secondary: May associate with mitochondrial nucleoids
- Distribution: Approximately 10-15% of total mitochondrial protein mass
Background
The study of Atp5A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [NCBI Gene - ATP5A1](https://www.ncbi.nlm.nih.gov/gene/498)
- [UniProt - ATP5A1](https://www.uniprot.org/uniprot/P25788)
- [Ensembl - ATP5A1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188039)
References
[Cadenas et al., Mitochondrial ATP synthesis in neurodegeneration (2010)](https://doi.org/10.1016/j.tibs.2010.05.004)
[Brown et al., ATP synthase and Alzheimer's disease (2014)](https://doi.org/10.1016/j.neurobiolaging.2013.12.001)
[Moree et al., Mitochondrial ATP synthase dysfunction in neurodegenerative diseases (2023)](https://doi.org/10.1016/j.nbd.2023.105879)
[Wang et al., ATP5A1 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1038/s41598-022-15642-4)
[Cheng et al., Targeting mitochondrial ATP synthase in Parkinson's disease (2021)](https://doi.org/10.1016/j.bbadis.2021.166123)Pathway Diagram
The following diagram shows the key molecular relationships involving ATP5A1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)